KIM-ANH DO to Adolescent
This is a "connection" page, showing publications KIM-ANH DO has written about Adolescent.
Connection Strength
0.095
-
Analysis of melanoma onset: assessing familial aggregation by using estimating equations and fitting variance components via Bayesian random effects models. Twin Res. 2004 Feb; 7(1):98-113.
Score: 0.013
-
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol. 2020 06; 95(6):612-622.
Score: 0.010
-
Demographic, clinical, and geographical factors associated with lack of receipt of physician recommended chemotherapy in women with breast cancer in Texas. Cancer Causes Control. 2019 Apr; 30(4):409-415.
Score: 0.009
-
Discriminant analysis of event-related potential curves using smoothed principal components. Biometrics. 1999 Mar; 55(1):174-81.
Score: 0.009
-
Predictive factors of age at menopause in a large Australian twin study. Hum Biol. 1998 Dec; 70(6):1073-91.
Score: 0.009
-
Risk of recurrent venous thromboembolism after a first oestrogen-associated episode. Data from the REVERSE cohort study. Thromb Haemost. 2010 Sep; 104(3):498-503.
Score: 0.005
-
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008 Aug 15; 112(4):975-80.
Score: 0.004
-
Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2007 Oct 10; 25(29):4648-56.
Score: 0.004
-
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007 Jun 01; 109(11):4679-85.
Score: 0.004
-
Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease. Leuk Res. 2007 Feb; 31(2):139-45.
Score: 0.004
-
Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk Res. 2004 Jun; 28(6):595-604.
Score: 0.003
-
Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease. Br J Haematol. 2003 Dec; 123(5):850-7.
Score: 0.003
-
Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Br J Cancer. 2002 May 20; 86(10):1555-60.
Score: 0.003
-
Simplified staging for hepatocellular carcinoma. J Clin Oncol. 2002 Mar 15; 20(6):1527-36.
Score: 0.003
-
A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial. Ann Oncol. 2002 Jan; 13(1):125-34.
Score: 0.003
-
Reconstructive management of cranial base defects after tumor ablation. Plast Reconstr Surg. 2001 May; 107(6):1346-55; discussion 1356-7.
Score: 0.003
-
Functional analysis of IgA antibodies specific for a conserved epitope within the M protein of group A streptococci from Australian Aboriginal endemic communities. Int Immunol. 1999 Apr; 11(4):569-76.
Score: 0.002
-
Correlation of the proliferative index of residual leukemia with outcome in patients treated with sequential high dose ara-C and asparaginase. Leukemia. 1990 May; 4(5):316-20.
Score: 0.001